GENE ONLINE|News &
Opinion
Blog

2021-08-16| China

Innovent Announces Gastric Cancer Trial Win for Tyvyt, Reveals Plans for Another China Approval

by Rajaneesh K. Gopinath
Share To
Earlier today, Innovent announced positive outcomes from a gastric cancer trial that evaluated Tyvyt (sintilimab injection) in combination with chemotherapy. Interim analysis shows that the combo therapy met the primary endpoint of overall survival in patients.

Approved originally for treating relapsed or refractory classical Hodgkin’s lymphoma in China, Tyvyt had recently bagged its third NMPA approval. The immunotherapy, a fully human IgG4 anti-PD-1 monoclonal antibody, was developed by Innovent in collaboration with Eli Lilly.

GO Prime with only $1.49 now

LATEST
Finnish Study Finds Brain Biomarkers for Alzheimer’s Detectable in Middle Age
2025-07-14
Blood Test Developed at Medical University of Vienna Predicts Multiple Sclerosis Risk Years Before Symptoms
2025-07-14
University of Tokyo Researchers Develop In Vivo System to Study Senescent Cells in Aging
2025-07-14
Relmada Therapeutics Ends Development of Depression Drug Esmethadone and Terminates Licensing Agreement
2025-07-14
Takeda Reports Positive Phase 3 Trial Results for Oveporexton in Narcolepsy Treatment
2025-07-14
Takeda Pharmaceuticals Reports Positive Phase 3 Trial Results for Narcolepsy Drug Targeting Daytime Sleepiness and Cataplexy
2025-07-14
Takeda Reports Positive Phase 3 Trial Results for Oveporexton Targeting Orexin Proteins in Narcolepsy Treatment
2025-07-14
EVENT
2025-07-23
BIO Asia–Taiwan 2025
Taipei, Taiwan
2025-08-08
HEALTHY AGEING TECH SHOW
Taipei, Taiwan
2025-08-09
MEDINFO 2025
Taipei, Taiwan
2025-09-03
BIO ASIA PACIFIC 2025
Bangkok, Thailand
2025-09-10
BIOHK 2025
Hong Kong
2025-10-01
Medical Japan 2025
Osaka, Japan
Scroll to Top